PART I Company Overview We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients. We aim to develop diff...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001590750-26-000007 | EDGAR | 101K words |
| 2025-03-03 | 2024-12-31 | 0001590750-25-000004 | EDGAR | 91K words |
| 2024-02-27 | 2023-12-31 | 0001590750-24-000007 | EDGAR | 81K words |
| 2023-03-09 | 2022-12-31 | 0001590750-23-000002 | EDGAR | — |
| 2022-03-11 | 2021-12-31 | 0001590750-22-000004 | EDGAR | — |
| 2021-03-26 | 2020-12-31 | 0001590750-21-000029 | EDGAR | — |
| 2020-03-13 | 2019-12-31 | 0001590750-20-000021 | EDGAR | — |
| 2019-03-14 | 2018-12-31 | 0001590750-19-000013 | EDGAR | — |
| 2018-03-15 | 2017-12-31 | 0001590750-18-000006 | EDGAR | — |
| 2017-03-24 | 2016-12-31 | 0001171843-17-001747 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001590750-26-000018 | EDGAR | 61K words |
| 2025-11-05 | 2025-09-30 | 0001590750-25-000020 | EDGAR | 62K words |
| 2025-08-06 | 2025-06-30 | 0001590750-25-000012 | EDGAR | 59K words |
| 2025-05-06 | 2025-03-31 | 0001590750-25-000008 | EDGAR | 57K words |
| 2024-11-12 | 2024-09-30 | 0001590750-24-000023 | EDGAR | 57K words |
| 2024-08-08 | 2024-06-30 | 0001590750-24-000019 | EDGAR | 55K words |
| 2024-05-08 | 2024-03-31 | 0001590750-24-000012 | EDGAR | 53K words |
| 2023-11-13 | 2023-09-30 | 0001590750-23-000013 | EDGAR | 55K words |
| 2023-08-08 | 2023-06-30 | 0001590750-23-000008 | EDGAR | 53K words |
| 2023-05-10 | 2023-03-31 | 0001590750-23-000003 | EDGAR | 48K words |
| 2022-11-14 | 2022-09-30 | 0001590750-22-000012 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001590750-22-000009 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-336691 | EDGAR | 3K words |
| 2026-03-30 | 0001193125-26-130433 | EDGAR | 9K words |
| 2026-02-26 | 0001193125-26-073391 | EDGAR | 3K words |
| 2025-11-05 | 0001193125-25-265711 | EDGAR | 4K words |
| 2025-10-23 | 0001193125-25-247410 | EDGAR | 27K words |
| 2025-10-21 | 0001193125-25-245206 | EDGAR | 1K words |
| 2025-10-20 | 0001193125-25-243039 | EDGAR | 2K words |
| 2025-08-06 | 0001193125-25-173983 | EDGAR | 4K words |
| 2025-07-30 | 0001193125-25-168614 | EDGAR | 1K words |
| 2025-06-24 | 0001193125-25-145741 | EDGAR | 16K words |
271 total filings indexed. 239 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001590750 |
| Ticker | VRDN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.viridiantherapeutics.com |
| Listed | 2014-06-18 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/VRDN (~200 tokens, structured JSON with cryptographic provenance)